chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received a Moderna booster on this date, having received a Johnson & Johnson Covid vaccine on 3/8/2021. About 2 hours after the injection, I noticed that I had some swelling in my tongue and throat. I would call the swelling mild. It is uncomfortable but does not prevent me from breathing, swallowing or speaking.
Client was given the Men group A component of the vaccine diluted with sterile water. Client notified, no adverse signs or symptoms reported.
This spontaneous case was reported by a consumer and describes the occurrence of RASH (mild rash) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Feb-2021, the patient experienced RASH (mild rash). At the time of the report, RASH (mild rash) outcome was unknown.            No concomitant products reported  No treatment products reported   This case was linked to MOD-2021-058113 (Patient Link).   This case was linked to MOD-2021-058113 (Patient Link).
Childs mom call after hours triage on 9/12 to report event was sent to ED and then was hospitalized with large local immunization reaction. D/C home later on 9/13/13.
Patient reported began on 12/26/2020 with soreness to left axillary /underarm area, within approx. 6 hours started having itching at site with quarter-sized knot to site, reports developed itching all over body. She contacted her primary doctor who advised her to begin taking Benadryl and applying cold compresses to the site. Spoke with patient again on 1/4/2021. she reports still had redness to area, but itching has subsided.
Patient complained of feeling dizzy and blurry vision 10 minutes after receiving the vaccination shot.  Patient found out she was pregnant yesterday that gestation was about 5 weeks ago.  She mentioned she had a granola bar for breakfast and nothing else before receiving the vaccination.  Water initially provided, vital signs taken with no improvement, gave juice and snacks and patient consumed it.  Patient with vitals taken multiple times after initials vitals taken.  Patent stated she felt improvement, not feeling dizzy and blurry vision subsided, final vitals taken and ambulation closely supervised with no issues to gait.  Patient left with boyfriend in a private car.
Initial information received on 15-Nov-2018 regarding an unsolicited valid non-serious case received from a pharmacist. This case is linked to case 2018SA317803 (same reporter). This case involves a 57 years old female patient who experienced broke out in a rash, while she received vaccine FLUZONE QUADRIVALENT. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE lot number not reported. On an unknown date, the patient developed a non-serious broke out in a rash unknown latency following the administration of INFLUENZA QUADRIVAL A-B VACCINE. (Other relevant tests included no lab test). Final diagnosis was broke out in a rash. It was not reported if the patient received a corrective treatment. The patient outcome is reported as Unknown for broke out in a rash. The reporter assessed the causal relationship with suspect vaccine as possible. List of documents held by sender: none.
tendonitis of both wrists-arthritis lt 1st metocarpophalangeal joint; rheumatoid like swelling of lt middle finger & terminal interphalange joint; swelling of both ankles;
D68.9 COAGULOPATHY, UNSPECIFIED TYPE 2/23/2022 DM 2 W RENAL MANIFESTATION
dizziness; headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 56 year-old male patient received bnt162b2 (BNT162B2), administration date 07Apr2021 (Batch/Lot number: unknown) at the age of 56 years as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DIZZINESS (non-serious) with onset Apr2021, outcome "unknown", described as "dizziness"; HEADACHE (non-serious) with onset Apr2021, outcome "unknown", described as "headache".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
PT HAD CHILLS, MUSCLE ACHES AND FLUSHING STARTING ON 10/8/17, SYMPTOMS WORSEN UNTIL 10/11/17. ON 10/12/17 PT IS STARTING TO FEEL BETTER AND WILL START TO TAKE MORE FLUID, INCREASE SLEEP AND TAKE TYLENOL AS NEEDED.
Information has been received from a physician concerning a 52 yr old female diabetic, who on 26Sep05 was vaccinated IM with a 0.5mL dose of pneumococcal 23v polysaccharide vaccine. On 28Sep05 about two days post vaccination, the pt experienced generalized arthralgia. Unspecified medical attention was sought. The pt was placed on naproxen. No diagnostic lab studies were performed. At the time of this report, the pt had not recovered. No product quality complaint was involved. Generalized arthralgia was considered to be disabling.  Follow up information indicated that in further evaluation this pt did not have the adverse reaction to pneumococcal 23v polysaccharide vaccine. Additional information is not expected.
Information has been received from a foreign legal firm regarding a case in litigation concerning a 30 month old female who on 12/4/00 was vaccinated with MMR II. Concomitant therapy on 12/04/00 included varicella virus vaccine live. It is alleged that on 01/16/02, unspecified initial symptoms started and that the pt "turned out to be affected by autistic syndrome and post-vaccinal thrombocytopenia due to the experimental prophylaxis vaccine P32 combined with MMR." It is further alleged that, "as documented by the evaluations conducted on the little girl," the pt suffered irreversible permanent damage. It is also alleged that the pt's parents, besides suffering existential damage, have been compelled to bear considerable medical expenses. Upon internal review the autism was considered to be an other medical event. Additional info has been requested.
Went for my yearly ckup & my doctor said I needed to have a second pneumonia shot. Almost 24 hours later I thought I was dying! All listed side effects except pt vomiting, hit at once. I was not warned of side effects! fever, chills, headache, muscle joint pain-lasted 3 days. my arm swelled from my shoulder to my elbow-itched & Red-lasted 6 days. Membranes in Nose swelled, No appetite for 3 days and felt exhausted. The name of the shot was PREVNAR
11:15pm 11/17/18 grunt like breathing, eyes wide open staring off to right and head turned to (R). She turned head when name called but blank stare and outfit soaked with drool per foster mom. She also developed bilateral upper extremity twitching ? started with (R) hand. EMS called per PCP recommendation. No time frame documented.
Vacc administered L arm by me. No local reaction immediate. On 11/22/09 started with low, chills, sweat-dizziness and nystagmus.
"Covid arm" rash at site of injection appeared several days after the first shot. Red rash appearance, about 2-3 inches in diameter. Slight itchiness of rash at first for a couple hours but the next day is only red and skin is warm to the touch in that area.
Some arm pain; Itchiness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Some arm pain) and VACCINATION SITE PRURITUS (Itchiness at injection site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003A21A) for COVID-19 vaccination.     The patient's past medical history included Cancer (13 year survivor).   On 05-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, the patient experienced PAIN IN EXTREMITY (Some arm pain) and VACCINATION SITE PRURITUS (Itchiness at injection site). At the time of the report, PAIN IN EXTREMITY (Some arm pain) outcome was unknown and VACCINATION SITE PRURITUS (Itchiness at injection site) was resolving.            Concomitant product used included hypertensive medication NOS.  No treatment was administered for the event.
This case was reported by a pharmacist via call center representative and described the occurrence of fatigue in a 51-year-old female patient who received SHINGRIX (batch number B334Y, expiry date 17th October 2020) for prophylaxis. On 26th May 2018, the patient received SHINGRIX (intramuscular) .5 ml. On an unknown date, less than a month after receiving SHINGRIX, the patient experienced fatigue, fever and malaise. On an unknown date, the outcome of the fatigue and malaise were not recovered/not resolved and the outcome of the fever was recovered/resolved. The reporter considered the fatigue, fever and malaise to be related to SHINGRIX. Additional details were provided as follows: The pharmacist said that one of his patients received the SHINGRIX. At the time of reporting the patient called the reporting pharmacist and said she was still experiencing fatigue and malaise but had recovered from the fever. The patient experienced 103 degree F fever that lasted a few days.
Patient states that after the imz she went home and slept she woke up at 11:30pm with tightness in the throat and very little voice, she had no voice the next day and called in sick to work, she worked the next day and lost her voice again on Friday. Additionally her eyes have been watering.
On 4APR91, pt recvd HIBTITER only; that evening had severe vomiting but was afebrile; hospitalized 5APR91; pt continued to vomit for the next 5 days; treatment included IV lfuids; 1 wk prior to immun pt completed a course of ATB for OM;
This spontaneous report was received from a physician via company representative, concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported. On 25-APR-2015, the patient was vaccinated with an improperly stored dose of COMVAX (lot number J013884; expiration date 19-AUG-2016) 0.5 ml "SDV;PK/10" (route of administration and anatomical location were not reported). On an unspecified dates, the COMVAX had nine temperature excursions: 488 hours, 40 hours, 64 hours, 72 hours, 328 hours, 88 hours, 64 hours, 1152 hours, 192 hours. The lowest recorded temperature was 28 F (-2.222222222 Celsius) while the highest recorded temperature was 48 F (8.88888889 Celsius). No adverse effects reported and no product quality complaint was involved. The vaccine status was reported as "in excursion". The vaccine storage criteria and the storage type of excursion were reported as "Refrigerator(R)". This is one of several cases from the same reporter. Additional information has been requested.
This spontaneous report as received from a physician refers to an unspecified patient of unknown age. The reporter stated on 14-JAN-2013 the unspecified patient might have been inadvertently administered TUBERCULIN PPD (manufacture: sanofi-Pasteur) instead of PNEUMOVAX23 but she was not sure. She stated that a blood sample was drawn to determine if the unspecified patient had pneumococcal titer levels that would an immune response that would be normal if there was a possibility that PNEUMOVAX23 was administered. No adverse effect reported. It was unspecified if the patient had sought medical attention. Additional information has been requested.
Large golf ball size lump at injection site, hot red raised and tender to touch approximately 2.5in in diameter.
Case number PHEH2017US003563, is an initial spontaneous report received from a nurse on 31 Jan 2017. This report refers to a 39 years old female patient. Past medical history and concomitant medications were not reported. The patient was vaccinated with FLUCELVAX QUADRIVALENT (batch number: not reported) at a dose of 0.5 ml intramuscularly on 27 Jan 2017. It was reported that temperature excursion was reported with FLUCELVAX QUADRIVLENT. The temperature excursion happened last week. Flu vaccine was given to one of the patients and the vaccines were discarded afterwards. It was reported that the customer wanted to know the next steps in treating the patient. The temperature of the vaccine did not exceed 77 degrees F and the excursion lasted overnight (24 hours). This was the first excursion. No adverse event was reported following this administration error.
if the patient has an allergies to either metamizole or marolac, the patient havent been getting covid vaccine; unknown if Covid vaccine administered  to patient having these allergies; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP).  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation; metamizole (METAMIZOLE) (Batch/Lot number: unknown). The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HYPERSENSITIVITY (non-serious), outcome "unknown", described as "if the patient has an allergies to either metamizole or marolac, the patient havent been getting covid vaccine; unknown if Covid vaccine administered  to patient having these allergies". The action taken for metamizole was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient inform us on 9/8 she had local reaction and on 9/09 she could not move her arm up and lymph nodes under arm are swollen. We informed her to contact her MD.
Swollen arm; Pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Swollen arm) and PAIN IN EXTREMITY (Pain in arm) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20a) for COVID-19 vaccination.     The patient's past medical history included Shoulder replacement. Concurrent medical conditions included Drug allergy (Sulpha).    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, the patient experienced PERIPHERAL SWELLING (Swollen arm) and PAIN IN EXTREMITY (Pain in arm). The patient was treated with PARACETAMOL (TYLENOL) for Swollen arm and Pain in arm, at an unspecified dose and frequency. In February 2021, PERIPHERAL SWELLING (Swollen arm) and PAIN IN EXTREMITY (Pain in arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information included Tylenol.   This case was linked to MOD-2021-034898 (Patient Link).
No Adverse Event; Pharmacist reports that they inadvertently administered a dose of the monovalent vaccine to a patient today, 06Mar2023 which was past the published expiry date.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Pharmacist reports that they inadvertently administered a dose of the monovalent vaccine to a patient today, 06Mar2023 which was past the published expiry date.) and NO ADVERSE EVENT (No Adverse Event) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 060B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 06-Mar-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 06-Mar-2023,  after starting mRNA-1273 (Spikevax), the patient experienced EXPIRED PRODUCT ADMINISTERED (Pharmacist reports that they inadvertently administered a dose of the monovalent vaccine to a patient today, 06Mar2023 which was past the published expiry date.). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Pharmacist reports that they inadvertently administered a dose of the monovalent vaccine to a patient today, 06Mar2023 which was past the published expiry date.) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Pharmacist reports that they inadvertently administered a dose of the monovalent vaccine to a patient today, 06Mar2023 which was past the published expiry date.).    No concomitant medication was reported.    Pharmacist reported that they inadvertently administered a dose of the monovalent vaccine to a patient on 06-Mar-2023 which was past the published expiry date.Expiration date: 26-Feb-2023. No treatment information was reported.
I developed severe, spontaneous hives a little over a week after my Moderna booster. I have had daily hives ever since (for 7 months). I have to take the maximum dose of antihistamines each day and I still have hives.
Developed fever of 100 degrees, shivers and cold and nausea.  This lasted all day, fever finally broke the next night.  Took Dramamine, which did not help.  Took a treatment of crushed ginger and honey which gave some relief from nausea.
I got a bad flu, starting evening after I got my 2nd Zoster Vaccine (Recombinant) and was in bed for 2 days; I also got swelling and bruising on left arm where I go the shot.
Headache-will wake me up. More severe at times, less at others. Constantly there.  Ringing in ears.  Comes and goes. Usually 20-30deconds-gradually gets louder/sharper before disappearing. Happens 8-10/hour when awake. No correlation with headache
my throat started to feel tight; Tingling (pin prick) sensation on forehead, down nose and upper lip area; little lightheaded; This is a spontaneous report from a contactable consumer (patient). A 45-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: not reported), dose 1 via unspecified route administration on 06Mar2021 (at 11:30 AM) as dose 1, single in left arm for covid-19 immunization (at the age of 45years). Patient was not diagnosed with COVID-19 prior to the COVID vaccine and since the vaccination. Patient did not receive other vaccine within four weeks prior to the COVID vaccine. The patient medical history included Known allergies: latex. The patient's concomitant medications were not reported. The patient had not taken any treatment for reported events. The patient experienced tingling (pin prick) sensation on forehead, down nose and upper lip area, little lightheaded and my throat started to feel tight on 06Mar2021 (at 11:45 AM). The outcome of the events was recovered on an unspecified date in 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Had warmness in his throat that went away; Started having pressure headaches in the upper back of his head; His resistance felt low; He felt stoned; pressure headaches; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL DISCOMFORT (Had warmness in his throat that went away), HEAD DISCOMFORT (Started having pressure headaches in the upper back of his head), GENERAL PHYSICAL HEALTH DETERIORATION (His resistance felt low), FEELING ABNORMAL (He felt stoned) and HEADACHE (pressure headaches) in an 81-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036A21A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Mar-2021, the patient experienced OROPHARYNGEAL DISCOMFORT (Had warmness in his throat that went away), HEAD DISCOMFORT (Started having pressure headaches in the upper back of his head), GENERAL PHYSICAL HEALTH DETERIORATION (His resistance felt low), FEELING ABNORMAL (He felt stoned) and HEADACHE (pressure headaches). At the time of the report, OROPHARYNGEAL DISCOMFORT (Had warmness in his throat that went away) had resolved and HEAD DISCOMFORT (Started having pressure headaches in the upper back of his head), GENERAL PHYSICAL HEALTH DETERIORATION (His resistance felt low), FEELING ABNORMAL (He felt stoned) and HEADACHE (pressure headaches) outcome was unknown.            No Concomitant  medication was reported No treatment medication was reported
The BUD was 13-APR-2023 and the vaccine was given on 14-APR-2023; No adverse event; Dose of moderna vaccine given beyond use by date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose of moderna vaccine given beyond use by date), PRODUCT STORAGE ERROR (The BUD was 13-APR-2023 and the vaccine was given on 14-APR-2023) and NO ADVERSE EVENT (No adverse event) in a 32-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 066H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 14-Apr-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .5 milliliter. On 14-Apr-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose of moderna vaccine given beyond use by date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The BUD was 13-APR-2023 and the vaccine was given on 14-APR-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose of moderna vaccine given beyond use by date), PRODUCT STORAGE ERROR (The BUD was 13-APR-2023 and the vaccine was given on 14-APR-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose of moderna vaccine given beyond use by date) and PRODUCT STORAGE ERROR (The BUD was 13-APR-2023 and the vaccine was given on 14-APR-2023).    Concomitant medications were not reported. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-721275 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-721275:Master case
Coughing; coughing up mucus; fatigue; shortness of breath; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Coughing), COUGH (coughing up mucus), FATIGUE (fatigue) and DYSPNOEA (shortness of breath) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038K20A and 006M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COUGH (Coughing), COUGH (coughing up mucus), FATIGUE (fatigue) and DYSPNOEA (shortness of breath). At the time of the report, COUGH (Coughing), COUGH (coughing up mucus), FATIGUE (fatigue) and DYSPNOEA (shortness of breath) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant information were not provided by the reporter. Treatment information were not provided by the reporter.
Pt has swelling of anterior thigh, left. Some induration and erythema with heat.